E
Etienne Dumont
Researcher at Hoffmann-La Roche
Publications - 9
Citations - 702
Etienne Dumont is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 647 citations.
Papers
More filters
Journal ArticleDOI
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Johannes Schüller,Jim Cassidy,Etienne Dumont,Brigitte Roos,Sarah Durston,Ludger Banken,Masahiro Utoh,Kazushige Mori,Erhard Weidekamm,Bruno Reigner +9 more
TL;DR: Capecitabine is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil preferentially in tumors, which is explained to a great extent by the activity of TP in colorectal tumor tissue, (the enzyme responsible for the conversion of 5′-DFUR to 5-FU), which is approximately four times that in adjacent healthy tissue.
Journal ArticleDOI
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections
Nicole E. Scangarella-Oman,Mohammad Hossain,Jennifer Hoover,Caroline R Perry,Courtney Tiffany,Aline Bergesch Barth,Etienne Dumont +6 more
TL;DR: Data for gepotidacin from nonclinical studies, including in vitro activity, in vivo animal efficacy, and pharmacokinetic (PK) and Pharmacokinetic/pharmacodynamic (PK/PD) models that informed dose selection for phase III clinical evaluation are reviewed.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of 9-cis-retinoic acid in healthy men.
Cornelia Weber,Etienne Dumont +1 more
TL;DR: The pharmacokinetics of 9‐cis‐retinoic acid were linear over the dose range studied and adverse events observed were consistent with findings of other retinoids and included headache and xeroderma at high dose levels.
Journal ArticleDOI
Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects
TL;DR: Gepotidacin was generally well‐tolerated, with no drug‐related serious adverse events reported, and these PK and safety data across a wide range of doses in healthy participants aged greater than or equal to 18 years support the development of gepotIDacin in further clinical studies.
Journal ArticleDOI
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea
Nicole E. Scangarella-Oman,Mohammad Hossain,Caroline R Perry,Courtney Tiffany,Marcy Powell,Brandon Swift,Etienne Dumont +6 more
TL;DR: A translational approach using in vitro pharmacokinetic/pharmacodynamic (PK/PD) and clinical data was used to select a gepotidacin dose for a phase III study.